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Abstract
Patients who develop a severe stenosis in biological pulmonary conduits previously implanted for pulmonary outflow trunk reconstructions
are treated either by surgical re-replacement, or by transcatheter stent-valve implantation through a femoral vein access. A catheter-based
sub-xyphoidian access through the right ventricle for stent-valve positioning in a pulmonary conduit has rarely been proposed. We describe
the case of a 20-year-old man who underwent a pulmonary trunk reconstruction for a congenital pulmonary valve dysplasia and a few years
later developed a stenosis in the pulmonary conduit. He was successfully treated with a 23 mm Edwards Sapien# stent-valve implantation in
pulmonary position, through an unusual right ventricular, sub-xyphoidian access and without contrast medium injections and pleura
opening.
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The stenosis is a severe complication following surgery for
pulmonary outflow trunk reconstruction with biological
conduits, as human cryopreserved homografts or bovine
jugular veins (ContegraW, Medtronic, Minneapolis, USA). The
re-operation for pulmonary conduit replacement under re-
sternotomy and cardiopulmonary bypass remains a high-risk
procedure with consistent morbidity and mortality [1]. The
arrival of new stent-valves has been heralded as an important
change in concepts and, recently, the use of transcatheter
techniques for pulmonary valve replacement through the
femoral vein (MelodyW valve, Medtronic, Minneapolis, USA)
has become routine in specialised cardiac care units [2—4]. In
spite of that, there are a few limitations related to the use of
this device in the presence of vena cava filters, femoral vein
thrombosis/stenosis or very large pulmonary conduits
(MelodyW valve limited to 22 mm). Moreover, the positioning
of catheter-based valves requires the injection of contrast
medium which is nephro-toxic at high concentration. A sub-
xyphoidian access for transcatheter valve implantation* Corresponding author. Address: Department of Cardiovascular Surgery,
Centre Hoˆpitalier Universitaire Vaudois (CHUV), 46, rue du Bugnon, CH-
1011 Lausanne, Switzerland. Tel.: +41 79 310 1386; fax: +41 21 314 2278.
E-mail address: enricoferrari@bluewin.ch (E. Ferrari).
1010-7940/$ — see front matter # 2009 European Association for Cardio-Thoracic
doi:10.1016/j.ejcts.2009.04.051without contrast medium injections, can be a valid alter-
native in selected patients.
2. Case report
We hospitalised a 20-year-old man who underwent, 5
years earlier, open heart surgery for pulmonary trunk
reconstruction (ContegraW conduit 22 mm, Medtronic,
Minneapolis, USA) in a congenital stenotic pulmonary valve
dysplasia plus a concomitant interventricular defect
closure. He was symptomatic for dyspnoea, fever and
fatigue and we made the diagnosis of conduit stenosis plus
sub-acute endocarditis; the trans-oesophageal echocardio-
gram (TEE) showed a pulmonary peak gradient of 45 mmHg
and a thick and dystrophic pulmonary valve with vegeta-
tions. The sub-acute endocarditis was treated conserva-
tively with intravenous antibiotics and 8 weeks later, the
vegetation disappeared, but the patient developed a
transitory antibiotic-related renal insufficiency. To
decrease the operative risk and prevent an acute renal
failure that could have occurred after cardiopulmonary
bypass (in re-operation) or contrast medium employment
(in trans-femoral approach), we decided for a sub-
xyphoidian stent-valve implantation without contrast
medium. We performed a pre-operative three-dimensional
(3D) computed tomography scan to analyse the pulmonarySurgery. Published by Elsevier B.V. All rights reserved.
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Fig. 1. A three-dimensional computer tomography scan showing the severe
stenosis in the ContegraW pulmonary conduit.
Fig. 2. A control computer tomography scan showing the implanted stent-
valve (SapienW valve, Edwards, Irvine, CA, USA) in the stenotic pulmonary
conduit.conduit. Coronary anomalies were not found (Fig. 1). The
operation was carried out under general anaesthesia.
Following our protocol for transcatheter valve implanta-
tion, a C-arm fluoroscopy, an intra-vascular ultrasound
(IVUS) and a TEE were use to identify the landing zone. The
surgical access was an uncommon sub-xyphoidian
approach: the scar of the previous surgical intervention
was extended for about 8 cm, with an incision under the
xyphoid process. Then, the diaphragmatic face of the right
ventricle was exposed and a pacemaker wire was fixed and
tested for rapid pacing. A double 2/0 purse-string suture
reinforced with pledgets was prepared in a zone of
myocardium without coronary arteries. After heparinisa-
tion (100 UI kg1), a guide wire and an 11 French sheet
were introduced into the right ventricle, towards the
pulmonary trunk, and an IVUS probe (nine French) was
guided over-the-wire into the right ventricle and across the
pulmonary valve. Once the stenosis and the pulmonary
bifurcation were identified, we marked the zone, under
fluoroscopy, with metal markers, as reported for endovas-
cular aorta repairs [5,6]. Then, we performed a pulmonary
valvuloplasty and a 23 mm Edwards SapienW valve implan-
tation (Edwards Lifescience, Irvine, CA, USA). The entire
procedure was carried out without contrast medium
injections and the result was excellent (Fig. 2); the TEE
confirmed low gradients and absence of paravalvular
leakage. The postoperative recovery was uneventful and
the patient was discharged after 10 days.
3. Discussion
Surgery for right ventricular outflow tract reconstruc-
tion is necessary in case of pulmonary atresia and Tetralogy
of Fallot, common arterial trunk and Rastelli operation in
great vessels transposition and ventricular septal defect
with pulmonary stenosis. However, although the survival ofbiological conduits is improving, re-operations are quite
common and they still involve morbidity and mortality.
Trans-femoral pulmonary valve replacement is emerging as
an alternative option and recent reports have confirmed
good short- and mid-term results [3,7—9]. The right
ventricular sub-xyphoidian access seems a valid alternative
in case of inaccessibility to the iliac/femoral vein axes, but
it requires the exclusive use of Edwards SapienW stent-
valves and needs more surgery when compared to the full
percutaneous trans-femoral access. However, the SapienW
valve is available in bigger diameters (23 mm and 26 mm)
and the indication can be extended to more adult patients
with larger conduits. Moreover the sub-xyphoidian access is
a full intra-pericardial procedure and could be strongly
indicated in case of severe respiratory disease. In this
report, the patient was suffering from a stenosed
pulmonary conduit and we decided on a right ventricular
sub-xyphoidian access. The procedure required less than
two and a half hours, the pleura were never opened and
the patient was extubated immediately after surgery. We
did not use a pulmonary pre-stenting (recommended for
MelodyW valve implantation) and we have never used
contrast medium: our present policy is to reduce (or avoid)
the amount of contrast medium employed during endograft
or stent-valve implantation and, as already demonstrated,
the IVUS seems the ideal tool for this purpose [5,6]. In
E. Ferrari et al. / European Journal of Cardio-thoracic Surgery 36 (2009) 595—597 597conclusion, transcatheter pulmonary valve replacement
through a sub-xyphoidian access is feasible and can be
performed without contrast medium injections and pleura
opening.
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